Production and In Vitro Characterization of Solid Dosage form Incorporating Drug Nanoparticles

REFERENCES

• P. V. Balimane, Y. H. Han, and S. Chong. 2006. Current industrial practices of assessin permeability and P-glycoprotein interaction. AAPS J. 8:E1–E13.
   PubMed Web of Science ®Google Scholar
• S. Byrn, S. Pfeiffer, M. Ganey, C. Hoiberg, and G. Poochikian. 1995. Pharmaceutical solids: A strategic approach to regulatory consideration. Pharm. Res. 12:945–954.
   PubMed Web of Science ®Google Scholar
• J. A. Carlson, H. J. Mann, and D. M. Canafax. 1983. Effect of pH on disintegration and dissolution of ketoconazole tablets. Am. J. Hosp. Pharm. 40:1334–1336.
   PubMedGoogle Scholar
• R. D. Connors, and E. J. Elder. 2004. Using a portfolio of particle growth technologies to enable delivery of drugs with poor water solubility. Drug. Deliv. Tech. 4 (8):78–83.
   Google Scholar
• M. T. Esclusa-Diaz, M. Gayo-Otero, M. B. Perez-Marcos, J. L. Vila-Jato, and J. J. Torres-Labandeira. 1996. Preparation and evaluation of ketoconazole-/-cyclodextrin multicomponent complexes. Int. J. Pharm. 142:183–187.
   Web of Science ®Google Scholar
• E. Galia, E. Nicolaides, D. Horter, R. Lobenberg, C. Reppas, and J. B. Dressman. 1998. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm. Res. 15:698–705.
   PubMed Web of Science ®Google Scholar
• J. Hecq, M. Deleers, D. Fanara, Vranckx, and K. Amighi. 2005. Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine. Int. J. Pharm. 299:167–177.
   PubMed Web of Science ®Google Scholar
• J. Hecq, M. Deleers, D. Fanara, Vranckx, P. Boulanger, S. Le Lamer, and K. Amighi. 2006. Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb-35440-3, a highly dosed poorly water-soluble weak base. Eur. J. Pharm. Biopharm. 64:360–368.
   PubMed Web of Science ®Google Scholar
• C. Jacobs, O. Kayser, and R. H. Muller. 2006. Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide. Int. J. Pharm. 196:161–164.
   Google Scholar
• K. P. Krause, and R. H. Muller. 2001. Production and characterization of highly concentrated nanosuspensions by high pressure homogenization. Int. J. Pharm. 214:21–24.
   PubMed Web of Science ®Google Scholar
• J. Lee. 2003. Drug nano- and microparticles processed into solid dosage forms: Physical properties. J .Pharm. Sci. 92:2057–2066.
   PubMed Web of Science ®Google Scholar
• J. Lee, and Yu Cheng. 2006. Critical freezing rate in freeze drying nanocrystal dispersions. J. Control. Rel. 11:185–192.
   Google Scholar
• H. B. Levine. 1982. Ketoconazole in the management of fungal disease. New York: Adis Press.
   Google Scholar
• E. M. Liversidge, G. G. Liversidge, and E. R. Cooper. 2003. Nanonizing: A formulation approach for poorly-water-soluble compounds. Eur. J. Pharm. Sci. 18:113–120.
   PubMed Web of Science ®Google Scholar
• E. M. Liversidge, P. Sarpotdar, J. Bruno, S. Hajj, L. Wei, N. Peltier, J. Rake, M. Shaw, S. Pugh, L. Pollin, J. Jones, T. Corbett, E. Cooper, and G. G. Liversidge. 1996. Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs. Pharm. Res. 13:272–278.
   PubMed Web of Science ®Google Scholar
• G. G. Liversidge, and P. Conzentino. 1995. Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int. J. Pharm. 125:309–313.
   Web of Science ®Google Scholar
• G. G. Liversidge, and K. C. Cundy. 1995. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs. Int. J. Pharm. 125:91–97.
   Web of Science ®Google Scholar
• P. K. Mididoddi, and M. A. Repka. 2007. Characterization of hot-melt extruded drug delivery systems for onychomycosis. Eur. J. Pharm. Biopharm. 66:95–105.
   PubMed Web of Science ®Google Scholar
• R. H. Muller, and B. H. L. Bohn. 1998. Nanosuspensions. R. H. Muller, S. Benita, and B. Bohm (Eds.), Emulsions and nanosuspensions for the formulation of poorly soluble drugs (pp. 143–147). Stuttgart: Medpharm Scientific.
   Google Scholar
• R. H. Muller, C. Jacobs, and O. Kayser. 2001. Nanosuspensions as particulate drug formulations in therapy rationale for development and what we can expect for the future. Adv. Drug. Deliv. Rev. 47:3–19.
   PubMed Web of Science ®Google Scholar
• H. Nogami, T. Nagai, and T. Yotsuyanagi. 1969. Dissolution phenomena of organic medicinals involving simultaneous phase changes. Chem. Pharm. Bull. 17:499–509.
   Web of Science ®Google Scholar
• C. Nystrom. 1998. Dissolution properties of soluble drugs: Theoretical background and possibilities to improve the dissolution behavior. R. H. Muller, S. Benita, and B. Bohm (Eds.), Emulsions and nanosuspensions for the formulation of poorly soluble drugs (pp. 143–147). Stuttgart: Medpharm Scientific.
   Google Scholar
• K. Peters, and R. H. Muller. 1996. Nanosuspensions for the oral application of poorly soluble drugs. In Proceeding European Symposium on Formulation of Poorly-available Drugs for Oral Administration (pp. 330–333). Paris: APGI.
   Google Scholar
• Pharmaceutical Technical Bulletin. In Improved Dissolution of Cationic Drugs with Polyplasdone Super Disintegrants. www.ispcorp.com.
   Google Scholar
• H. J. Ploehn, and W. B. Russel. 1990. Interaction between colloidal particles and soluble polymers. Adv. Chem. Engg. 15:137–228.
   Google Scholar
• U. Shah, C. Vemavarapu, V. Askins, M. Lodaya, P. Elzinga, and M. J. MollanJr.. 2006. Nanoparticle formation: A modular high pressure system to enhance biopharmaceutical properties of poorly soluble drugs. Pharm. Tech.
   Google Scholar
• G. Van den Mooter, M. Wuyts, N. Blaton, R. Busson, P. Grobet, P. Augustijns, and R. Kinget. 2001. Physical stabilization of amorphous ketoconazole in solid dispersions with polyvinylpyrrolidone K25. Eur. J. Pharm. Sci. 12:261–269.
   PubMed Web of Science ®Google Scholar
• J. W. M. Van der Meer, J. J. Keuning, H. W. Scheijgrond, J. Heykants, J. Van Cutsem, and J. Brugmans. 1980. The influence of gastric acidity on the bioavailability of ketoconazole. J. Antimicrob. Chemother. 6:552–554.
   PubMed Web of Science ®Google Scholar